Eosinophilic/ANCA-negative: favor IL-5 or IL-5Rα inhibition, with escalation to IL-5Rα agents (e.g., benralizumab) in patients with persistent eosinophilia, relapse after IL-5 therapy, or preference for single-dose administration every 4 weeks. This evidence concerns the gene IL5RA and Increased total eosinophil count.